iShares U.S. Pharmaceuticals ETF Rating $94.75 0.00 (0.00%) As of 06/12/2026 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsShort InterestBuy This Stock iShares U.S. Pharmaceuticals ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.IHE Aggregate RatingModerate Buy 2.73Holdings in IHE have an aggregate rating of Moderate Buy based on 318 analyst ratings issued in the past year covering 25 companies (92.4% of the portfolio).IHE Aggregate Price Target$94.75High Prediction$94.75Average Prediction$94.75Low Prediction$94.75Holdings in IHE have an aggregate price target of $94.75 and a range of $94.75 to $94.75 covering 25 companies (92.4% of the portfolio).IHE Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy3 Buy rating(s)Moderate Buy15 Moderate Buy rating(s)Hold6 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by iShares U.S. Pharmaceuticals ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 IHE Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings24.56%LLYEli Lilly and Company$1,137.01+0.4%4.1028 of 5 stars2.87$1,227.74 8.0%30Trending NewsAnalyst Revision20.74%JNJJohnson & Johnson$240.57-0.1%4.417 of 5 stars2.74$253.04 5.2%27Trending NewsInsider Trade5.01%RPRXRoyalty Pharma$54.874.569 of 5 stars3.00$53.71 -2.1%7Positive News4.85%VTRSViatris$16.483.2458 of 5 stars2.43$17.50 6.2%7News CoveragePositive News4.40%MRKMerck & Co., Inc.$119.05+0.0%4.468 of 5 stars2.68$128.18 7.7%19Trending NewsOptions VolumeGap Up4.05%PFEPfizer$26.19-0.1%3.842 of 5 stars2.25$28.82 10.1%20Trending NewsAnalyst Downgrade4.01%BMYBristol Myers Squibb$57.05-0.1%4.7181 of 5 stars2.37$61.31 7.5%19Trending News3.70%JAZZJazz Pharmaceuticals$230.563.3405 of 5 stars2.84$246.06 6.7%19Trending NewsInsider Trade3.08%ELANElanco Animal Health$24.19+0.1%3.5723 of 5 stars2.77$28.20 16.6%13Positive News2.87%ZTSZoetis$79.51-0.1%4.9653 of 5 stars2.33$133.92 68.4%15Trending NewsGap Up2.77%AXSMAxsome Therapeutics$255.171.6771 of 5 stars2.95$256.79 0.6%212.01%CORTCorcept Therapeutics$82.913.8275 of 5 stars2.75$88.83 7.1%8Positive News1.29%LGNDLigand Pharmaceuticals$255.542.4415 of 5 stars2.88$257.71 0.9%8Insider Trade1.27%LQDALiquidia$71.232.7793 of 5 stars2.90$60.29 -15.4%10Insider Trade1.23%INDVIndivior$38.482.1093 of 5 stars3.00$39.33 2.2%70.90%OGNOrganon & Co.$13.46+0.1%2.932 of 5 stars1.71$11.40 -15.3%7Positive News0.89%CRNXCrinetics Pharmaceuticals$34.473.2309 of 5 stars2.90$76.13 120.8%100.72%AMRXAmneal Pharmaceuticals$16.202.332 of 5 stars2.71$15.80 -2.5%7Analyst Downgrade0.67%SUPNSupernus Pharmaceuticals$44.413.4166 of 5 stars2.43$62.17 40.0%7Gap Up0.65%EWTXEdgewise Therapeutics$34.832.9637 of 5 stars2.78$44.22 27.0%9Gap Up0.63%TARSTarsus Pharmaceuticals$61.953.3369 of 5 stars2.78$90.67 46.4%90.61%DFTXDefinium Therapeutics$24.752.9667 of 5 stars3.00$37.92 53.2%15Options Volume0.58%PBHPrestige Consumer Healthcare$47.87+0.1%4.4087 of 5 stars2.17$70.75 47.8%60.48%NKTRNektar Therapeutics$59.382.644 of 5 stars2.73$149.63 152.0%110.46%ELVNEnliven Therapeutics$46.132.7957 of 5 stars2.86$61.50 33.3%7Trending NewsGap DownHigh Trading Volume This page (NYSEARCA:IHE) was last updated on 6/15/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares U.S. Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share iShares U.S. Pharmaceuticals ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IHE Stock Alerts